Comprehensive RNA Cancer Panel Sequencing Service provides highly multiplexed target selection of genes implicated in cancer research. Specifically, over 600 genes in the Wellcome Trust Sanger Institute Cancer Gene Census are included. This is the most comprehensive cancer RNA panel sequencing service available to date.
Discover common and rare genetic mutations including point mutations and low-frequency aberrations
Extensive multiplexing flexibility enables a more cost-effective assay
Ultra-deep sequencing of targeted regions to detects rare mutations
Comprehensive bioinformatics options for robust downstream analysis
Fast turnaround time
Paired-end sequence data from the most cutting-edge sequencing platforms
Dedicated, on-going support from experienced abm scientists
SKU
IT30010
Applications
Cancer biomarker discovery
Cancer mechanism study
Cancer therapeutic target discovery
Design genetic tests, such as for pharmacogenomics or oncology
